Iterative Health Raises $77M in Series C Funding

As part of the financing, Ajay Agrawal, Co-Founder and Partner at Intrepid Growth Partners, will join Iterative Health’s Board of Directors. Anthony Philippakis, General Partner at GV (Google Ventures), will join as a board observer.

The new funding will help Iterative Health expand into additional medical areas beyond gastroenterology and hepatology, including cardiology and obesity, and into new regions. The company will continue building partnerships with major healthcare groups, adding to its work with GI Alliance, OneGI, and U.S. Heart & Vascular.

Clinical trials are important for turning research into patient care, but many challenges slow this process. Over half of research sites enroll one or fewer patients per study and nearly 90% of U.S. trials fail to meet enrollment targets on time showing how difficult and complex the system has become.

Iterative Health is addressing these challenges by building a robust clinical research network that integrates research into patient care. Unlike traditional models, it focuses on helping research sites succeed by using centralized operations, skilled teams, AI technology and deep trial expertise. This approach helps sponsors and CROs access top performing sites, and diverse patients, speeding up trials and improving outcomes.

Iterative Health now operates a global network of over 100 research sites across North America, Europe, India, and Australia, with partnerships across more than 40 pharma, biotech, and research organizations. Compared to industry standards for IBD trials, it activates sites twice as fast—cutting startup time by up to 3 months—and achieves 3x higher patient enrollment, with more than 2 patients enrolled each business day across its network.

Iterative Health’s U.S. GI and hepatology network has grown significantly, and the company continues to partner with healthcare providers that want to make research a core part of patient care—from new trial sites to experienced ones expanding their work. At the same time, it is growing into new medical areas to support the next phase of expansion across its network.

Read More:Versana Raises $43 Million Led by BNP Paribas

“Intrepid invests in growth-stage companies that harness the power of AI to execute profound system redesigns that vastly enhance productivity across their industry,” said Ajay Agrawal, Co-Founder & Partner of Intrepid Growth Partners. “Iterative Health is a perfect example of this thesis, having purpose-built its proprietary technology to power a revolutionary clinical trial network that delivers unparalleled speed and scale to the pharmaceutical sector.”

“Clinical research remains the biggest bottleneck in drug development today. Iterative Health is solving this by using AI to accelerate trial enrollment times and bring new medicines to market faster. Jonathan and his team possess the technical depth and operational expertise needed to tackle clinical trial complexity at scale, and we’re excited to support Iterative Health as they expand to new therapeutic areas,” said Anthony Philippakis, General Partner of GV.

“Every delay in a clinical trial is a delay for patients whose outcomes depend on faster access to innovation. By keeping our physician partners and their patients at the center of our model, we’ve built a system that delivers high-performance site execution at scale,” said Jonathan Ng, MBBS, Founder and CEO of Iterative Health. “We are excited to bring greater scale to our model in a variety of new therapeutic areas together.”

About Iterative Health

Founded in 2017 by Jonathan Ng, Iterative Health is based in Cambridge, Massachusetts, and New York. It is a healthcare technology and services company that helps speed up clinical research to improve patient outcomes. Combining clinical trial expertise with AI helps research teams and sponsors bring new treatments to patients faster.

Read More:pmtbox Raises $15M in Seed Funding Led by Tandem Ventures